by MM360 Staff | Sep 27, 2020 | Featured News, Myeloma News
Updated results from a previously published cohort was published in Clinical Transplant. 92 newly diagnosed myeloma patients who received tandem transplant were compared them with 81 contemporary patients who received autologous transplant only. With a median...
by MM360 Staff | Sep 22, 2020 | Featured News, Myeloma News
FDA set a target action date of March 27, 2021 Ide-cel is the first CAR T cell therapy accepted for regulatory review for multiple myeloma Bristol Myers Squibb and bluebird bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority...
by MM360 Staff | Aug 26, 2020 | CME
Start Activity Nursing and Allied Health Online Seminar Wednesday 26 August 2020, 7pm-8:45pm Myeloma Australia is pleased to invite you to a free online, interactive educational event for nurses and allied health professionals. This is an excellent opportunity to...
by MM360 Staff | Jul 8, 2020 | Featured News, Myeloma News
The U.S. Food and Drug Administration (FDA) has approved oral XPOVIOTM (selinexor), a nuclear export inhibitor, in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four...
by MM360 Staff | Jun 25, 2020 | Featured News, Myeloma News, Videos
We just added a series of videos with two of the world leading experts in the treatment of myeloma. Dr. Xavier Leleu from the Centre Hospitalier Universitaire de Lille and Dr. Sagar Lonial from Emory University School of Medicine discuss the highlights of new myeloma...
